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DOI 10.1016/j.ccr.2011.07.018SUMMARYInactivation of the TCA cycle enzyme, fumarate hydratase (FH), drives a metabolic shift to aerobic glycolysis
in FH-deficient kidney tumors and cell lines from patients with hereditary leiomyomatosis renal cell cancer
(HLRCC), resulting in decreased levels of AMP-activated kinase (AMPK) and p53 tumor suppressor, and
activation of the anabolic factors, acetyl-CoA carboxylase and ribosomal protein S6. Reduced AMPK levels
lead to diminished expression of the DMT1 iron transporter, and the resulting cytosolic iron deficiency
activates the iron regulatory proteins, IRP1 and IRP2, and increases expression of the hypoxia inducible
factor HIF-1a, but not HIF-2a. Silencing of HIF-1a or activation of AMPK diminishes invasive activities,
indicating that alterations of HIF-1a and AMPK contribute to the oncogenic growth of FH-deficient cells.INTRODUCTION
Understanding the underlying mechanisms of metabolic alter-
ations in cancer, particularly the metabolic shift to aerobic
glycolysis, has the potential to improve cancer diagnosis and
provide the foundation for novel therapeutic approaches (Kaelin
and Thompson, 2010). The TCA cycle plays a key role in energy
production as well as biosynthesis of lipid and amino acids, and
mutations of the TCA cycle genes, fumarate hydratase (FH) and
succinate dehydrogenase (SDH), are associated with tumor
formation (Baysal et al., 2000; King et al., 2006; Tomlinson
et al., 2002; Toro et al., 2003). Germline mutations of FH areSignificance
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Canassociated with the development of hereditary leiomyomatosis
and renal cell cancer (HLRCC) (Tomlinson et al., 2002), whereas
germline mutations in SDH are associated with paragangliomas
(PGL), pheochromocytomas (PHEO), and renal cell carcinoma
(RCC) (Baysal et al., 2000; Hao et al., 2009). HLRCC patients
are predisposed to the development of cutaneous and uterine
leiomyomas and an aggressive form of type II papillary kidney
cancer that is characterized by distinctive architectural and
morphologic features (Launonen et al., 2001; Merino et al.,
2007). HLRCC renal tumors differ from other genetically defined
types of hereditary renal cancers in that they often present as
solitary lesions with a propensity to metastasize early to regionalphosphorylation to aerobic glycolysis (the Warburg effect).
es a glycolytic shift and decreases the levels of the master
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Altered Glucose and Iron Metabolisms in FH/ RCCand distant lymph nodes. Previous studies have shown that FH
deficiency results in the accumulation of fumarate, which inhibits
prolyl hydroxylases (PHDs) and impairs HIF-1a and HIF-2a
degradation (Isaacs et al., 2005; Pollard et al., 2005). Accumula-
tion of HIF has been proposed to promote tumorigenesis through
dysregulation of growth factors VEGF, TGF-a and PDGF, the
Glut-1 glucose transporter, and glycolytic enzymes (Isaacs
et al., 2005; Pollard et al., 2005; 2007; Semenza, 2009).
Recently, UOK262, a kidney cancer cell line derived from a
retroperitoneal metastasis in a patient with recurrent HLRCC
kidney cancer (Yang et al., 2010), exhibited ‘‘precisely the
properties expected of a Warburg tumor’’ (Bayley and Devilee,
2010). Warburg observed that cancer cells depend on glycol-
ysis rather than oxidative phosphorylation (OXPHOS) for
energy production and he theorized that abnormalities in mito-
chondrial energy production constituted a central aspect of
carcinogenesis (DeBerardinis et al., 2008; Warburg, 1956). In
UOK262 cells, loss of functional FH impairs the TCA cycle,
imposing a need for metabolic transformation. As a result,
UOK262 cells exhibit extremely low respiration rates, elevated
levels of HIF-1a and Glut-1, increased glucose dependence,
and increased lactate production (Sudarshan et al., 2009;
Yang et al., 2010).
The AMP-activated protein kinase (AMPK) plays a key role in
intracellular metabolic sensing and adaptation (Hardie, 2007)
and occupies a central position in a complex metabolic network
implicated in tumor formation (Jones and Thompson, 2009; Luo
et al., 2005). AMPK is a highly conserved heterotrimeric serine/
threonine protein kinase complex composed of a catalytic
a subunit and regulatory b and g subunits, each of which is en-
coded by two or three distinct genes (a1, 2; b1, 2; g1, 2, 3).
AMPK is activated typically, but not exclusively, by an increase
in the AMP:ATP ratio. The enzymes regulated by AMPK include
key regulators of protein, fatty acid, and glycerolipid syntheses,
such as the mammalian homolog of target of rapamycin (mTOR),
acetyl-CoA carboxylase (ACC), the transcriptional regulator
sterol-regulatory-element-binding-protein 1C (SREBP-1C), and
fatty acid synthase (FAS). Once activated, AMPK switches on
ATP-producing catabolic pathways (such as fatty acid oxidation
and glycolysis) and switches off ATP-consuming anabolic
pathways (such as protein and fatty acid synthesis), both by
short-term effects on phosphorylation and by long-term effects
on gene expression. Conversely, when AMPK activities are
reduced, fatty acid and protein biosynthetic pathways are acti-
vated through multiple mechanisms, including dephosphoryla-
tion of ACC and phosphorylation of ribosomal protein S6 through
the mTOR signaling pathway.
Here we have examined the metabolic status of FH-deficient
HLRCC kidney cancer tumor tissues and two distinct HLRCC
kidney cancer cell lines, focusing on the aerobic glycolysis of
FH-deficient cells, and associated changes in AMPK, HIFa
subunits, and iron metabolism.
RESULTS
Glycolytic and Tumorigenic Features of FH-Deficient
Cells Were Reversed by Restoration of FH Activity
We measured the levels of TCA cycle metabolites in UOK262
cells and found that fumarate levels were markedly increased,316 Cancer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inand malate levels were correspondingly low in UOK262 com-
pared with HK-2 cells, consistent with FH dysfunction (Fig-
ure 1A), and these abnormalities were reversed by stable trans-
fection of wild-type FH in UOK262 (UOK262-WT) (Figure 1A). To
examine tumorigenicity of the HLRCC cell line, UOK262 cells
were injected subcutaneously into nude mice. Palpable tumors
developed within 32 days, with a tumor doubling time of
17 days. Animals injected with UOK262-WT did not develop
tumors (Figure 1B), indicating that FH dysfunction was required
for tumor growth. We measured oxygen consumption and
lactate production in UOK262 cells (Sudarshan et al., 2009;
Yang et al., 2010) and in a recently derived HLRCC cell line,
UOK268. Consistent with a metabolic switch to glycolytic
metabolism, we observed low oxygen consumption rates and
high lactate production in both UOK262 and UOK268 cells
compared with HK-2 cells (Figure 1C). In addition, UOK262 cells
displayed low complex I activities (Figure 1D), and electron
microscopy studies revealed swollen mitochondria with severe
fragmentation of the cristae in UOK262 cells, similar to abnor-
malities found in non-HLRCC renal cells (UOK117C4 and 786-
0WT) exposed to 3-NPA, an inhibitor of the TCA cycle enzyme
SDH (Figure 1E). In contrast to most other types of genetically
defined kidney cancers, we observed that metastatic HLRCC
kidney tumors nearly uniformly exhibit intense fluorodeoxyglu-
cose uptake on PET scan (Figure 1F), consistent with the
increased dependence on glycolysis observed in HLRCC cell
lines in vitro.
Evidence for Glycolysis-Associated Cytosolic Iron
Deficiency in FH-Deficient RCC
Recent studies have suggested that IRPs, cytosolic proteins
that sense iron levels and regulate transcripts containing iron-
responsive elements (IREs) (Muckenthaler et al., 2008; Rouault,
2006), are important in tumorigenesis (Maffettone et al., 2010;
Zhang et al., 2008). When cytosolic iron levels are low, binding
of IRPs to IREs in the 50UTR of transcripts represses translation,
whereas binding to IREs in the 30UTR generally stabilizes the
transcripts. When cytosolic iron levels are high, IRPs do not
bind to IREs (Figure 2A). IRE-binding activities of IRPs were
markedly higher in UOK262 cells than in control cells (Figure 2B),
suggesting that cytosolic iron levels were lower in UOK262 cells.
Quantitative RT-PCR showed that transcript levels of IRP1 and
IRP2were not increased in UOK262 cells (not shown). Increased
IRP1 activities in UOK262 cells correlated with decreased
cytosolic aconitase activities (Figure 2C), consistent with the
conversion of IRP1 to the IRE-binding form in iron-deficient cells.
Increased IRP2 activity in UOK262 cells correlated with the
stabilization of IRP2 protein in iron-deficient cells (Figure 2D).
Levels of the IRP target, TfR1, were higher in UOK262 cells
(Figure 2E), consistent with activation of IRPs. Fumarate accu-
mulation did not account for the increased levels of IRP2 (Figures
S1A and S1B, available online).
Because UOK262 cells depend on high glucose for growth
(Yang et al., 2010), these cells were routinely cultured in media
containing 25 mM D-glucose (normal serum glucose: 4-6 mM).
Interestingly, activation of IRPs decreased in UOK262 cells
cultured in lower levels of glucose, whereas changes in glucose
concentrations did not affect IRP activities and IRP2 stability
in non-HLRCC cells, suggesting that features of the glycolyticc.
Figure 1. Mutations in FH compromised TCA cycle function and drove an oncogenic shift to aerobic glycolysis
(A) GC/MS analysis of TCA cycle intermediates (+/ SD) in HK-2, UOK262, and UOK262-WT cells.
(B) Growth curves of UOK262 and UOK262-WT xenografts in nude mice (n = 10 for each group) as assessed by tumor volume.
(C) Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR, an indicator of glycolytic rate) in UOK262 andUOK268 cells comparedwith HK-2
cells upon changes from 0.5 mM to 25 mM glucose. The vertical blue lines A and B signify the time at which 25 mM glucose was infused. The ECAR plots were
shown in percentage to demonstrate the fold enhancement in response to 25-mM glucose infusion.
(D) Respiratory complex I activity and protein levels (+/ SD) in UOK262 cells. Results from non-HLRCC renal cell lines, HEK293, 786-0WT, and UOK117C4, are
presented as fold-differences compared with those of UOK262 cells.
(E) Electronmicroscopy of mitochondrial morphology (arrows) in UOK262 cells and in non-HLRCC cells (UOK117C4 and 786-0WT) treatedwith the SDH inhibitor,
3-NPA. Scale bar represents 0.5 mm.
(F) Positron emission tomography (PET) with fluorodeoxyglucose (18FDG) in an HLRCC patient with advanced RCC demonstrated glucose uptake (black) in
multiple metastases (arrow points to a representative hepatic metastasis).
All data are representative of 3 or more independent experiments. Statistical analyses were performed by Student’s t test for paired samples. See also Table S1.
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(Figures 2F and 2G; Figures S1C–E).
Contribution of Cytosolic Iron Deficiency to
Misregulation of HIFa Proteins in FH-Deficient RCC
Changes in cytosolic iron levels and IRP activities can potentially
have competing effects on HIF-1a and HIF-2a levels. Because
PHDs require iron for their enzymatic activities, decreased
cellular iron levels would be expected to diminish the degrada-
tion of HIF-1a and HIF-2a proteins (Bruick and McKnight,
2001; Epstein et al., 2001). We observed that HIF-1a protein
levels were markedly elevated in HLRCC tumor specimens
(Figure 3A), in agreement with previous reports (Isaacs et al.,
2005; Pollard et al., 2005). Similarly, HIF-1a protein levels were
higher UOK262 cells (Figure 3B) and UOK268 cells (Figure 3C)
compared with non-HLRCC renal cells. Fumarate accumulationCanwas previously shown to inhibit PHDs (Isaacs et al., 2005; Pollard
et al., 2005). However, our results suggest that an additional
mechanism may drive the increase of HIFa in HLRCC: reduced
cytosolic iron levels (as evidenced by activation of IRPs) may
further stabilize HIFa proteins by inhibiting PHD activities.
Furthermore, iron starvation would be expected to have different
effects on expressions of the two HIFa subunits, because
previous studies have shown that the HIF-2a transcript contains
an IRE in its 50UTR, and translation of the HIF-2a transcript is
repressed by IRPs when cytosolic iron levels decrease (Sanchez
et al., 2007; Zimmer et al., 2008). We observed that HIF-2a levels
were elevated in mouse embryonic fibroblasts (MEFs) that
lacked IRP1 (Figure 3D), indicating that translational repression
by activated IRP1 contributes significantly to the regulation
of HIF-2a levels under both iron replete and iron-depleted
conditions. UOK262 cells exhibited low HIF-2a protein levelscer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inc. 317
Figure 2. Evidence for glycolysis-associated cytosolic iron deficiency and IRP activation in FH-deficient cancer cells
(A) Schematics for iron-dependent regulation of IRP1 and IRP2. When iron is abundant, IRP2 is degraded, whereas IRP1 is converted to cytosolic aconitase
(c-ACO). When iron is scarce, IRP2 is stabilized, whereas IRP1 loses its Fe-S cluster, and both IRPs bind to IREs with high affinity.
(B) IRP activities in UOK262 and non-HLRCC cells (786-0WT and UOK117C4) cultured for 16-20 hr with or without 50 uM deferoxamine (Dfo) or 100 ug/mL ferric
ammonium citrate as assessed by gel-shift assays. Immunoblots of tubulin were used as loading controls.
(C) Mitochondrial and cytosolic aconitase (m-ACO and c-ACO) activities in UOK262 and non-HLRCC cells (786-0WT and UOK117C4) were assessed by in-gel
aconitase activity assays.
(D) Immunoblots of IRP1 and IRP2 proteins in UOK262 and non-HLRCC cells (786-0WT and UOK117C4).
(E) Immunoblots of TfR1 in HEK293, 786-0WT, and UOK262 cells.
(F) IRP activities in UOK262 cells cultured with different glucose and pyruvate levels for 48 hr.
(G) Immunoblots of IRP2 protein in UOK262 cells and 786-0WT cells cultured in different concentrations of D-glucose.
See also Figure S1.
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and iron-depleted conditions, consistent with translational
repression by activated IRPs. Similarly, UOK268 cells exhibited
high HIF-1a and low HIF-2a protein levels (Figure 3C). These
results suggested that IRP-mediated repression of HIF-2a trans-
lation selectively attenuated the increase in HIF-2a that was
partly driven by iron starvation, whereas HIF-1a expression
was unaffected by IRP activation (Figure S2).
Reduced AMPK Levels Resulted in Activation of
Anabolic Factors and Activation of IRPs in UOK262 Cells
To understand how a mitochondrial TCA cycle dysfunction can
result in changes in two cytosolic iron-sensing proteins, we
examined signaling pathways that are important in metabolic
adaptations. We observed that AMPKa-p levels were lower in
HLRCC renal tumor specimens compared with normal kidney
tissue (Figure 4A). Levels of AMPKa, AMPKb1, phosphorylated
AMPKa (AMPKa-p), phosphorylated ACC (ACC-p, an AMPK
effector), and phosphorylated Akt were also low in UOK262 cells
compared with several non-HLRCC kidney cell lines (HK-2,
HEK293, 786-0WT) (Figure 4B), suggesting that the increased
glycolysis in FH-deficient cancer cells did not result from activa-
tion of AMPK or Akt (Elstrom et al., 2004; Marsin et al., 2000).
Quantitative RT-PCR indicated that levels of AMPKa1 and
AMPKb1 transcripts were relatively low in UOK262 cells (Fig-
ure 4C). Notably, the AMP:ATP ratio in UOK262 cells was318 Cancer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Incomparable with HK-2 cells (Figure 4D), suggesting that the
decrease in AMPKa-p levels in UOK262 cells was not caused
by changes in the AMP:ATP ratio. Because low AMPK activity
would be expected to decrease phosphorylation of ACC and
to activate mTOR, we evaluated these AMPK targets. We
observed reduced levels of ACC-p (Figure 4B), which would be
expected to increase the synthesis of the key fatty acid biosyn-
thetic intermediate, malonyl-CoA. In addition, we observed
constitutive activation of the ribosomal protein S6, an mTOR
downstream effector (Zhang et al., 2003) (Figure 4E). These
results suggested that reduced AMPK levels might promote
growth in FH-deficient renal cancer cells by enhancing fatty
acid and protein biosynthesis (Luo et al., 2005; Menendez and
Lupu, 2007).
We asked if reduced AMPK levels could activate IRPs by
examining non-HLRCC cells that were treated with the AMPK
inhibitor, AraA (Musi et al., 2001), or the AMPK activators, met-
formin and AICAR. Treatment with AraA reduced the levels of
AMPKa-p and increased IRP activities (Figure 4F), whereas
treatment with metformin or AICAR decreased IRP activities
(Figures 4G and 4H), revealing a role of AMPK in the regulation
of intracellular iron metabolism in mammalian cells. Notably,
AMPKa-deficient MEFs that are deficient in both AMPKa1 and
AMPKa2 (Laderoute et al., 2006) exhibited increased levels of
IRP2 compared with wild-type MEFs (Figure 4I), further indi-
cating that AMPK levels affect IRP expression.c.
Figure 3. Contribution of cytosolic iron deficiency and IRP activities to the misregulation of HIFa proteins in FH-deficient cells
(A) Immunohistochemistry of HIF-1a (dark brown staining) in healthy kidney tissue and HLRCC renal tumors. Scale bar represents 30 mm.
(B) Immunoblots of HIF-1a and HIF-2a in UOK262 compared with HEK293, 786-0WT and UOK117C4 cells.
(C) Immunoblots of HIF-1a and HIF-2a in UOK268 compared with HEK293 and 786-0WT cells.
(D) Immunoblots of HIF-2a in IRP1+/+ and IRP1/ MEF grown in normal media or treated with iron chelator DFO.
(E) HIF-2a mRNA levels (+/ SD) in iron-replete (-Dfo) or iron-depleted (+Dfo) HEK293, 786-0WT, UOK117C4, and UOK262 cells as assessed by qRT-PCR.
Data were normalized to actin expression.
See also Figure S2.
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Transporter
Although IRP1 and IRP2 activities can be differentially regulated
by many factors (Rouault, 2006), the most likely cause for simul-
taneous activation of both IRPs is cytosolic iron depletion. We
observed that the protein levels of DMT1 (Tabuchi et al., 2002),
which transport iron from the endosome into the cytosol after
iron uptake via TfR1 (Mims and Prchal, 2005), were extremely
low in UOK262 cells (Figure 5A). DMT1 transcript levels in
UOK262 cells were 2-10 fold lower compared with non-HLRCC
cells (Figure S3). Iron depletion with Dfo did not significantly
increase DMT1 levels in UOK262 cells, unlike in HEK293 and
UOK117C4 cells (Figure 5B). These results suggested that
reduced iron uptake through DMT1 caused the activation of
IRPs in UOK262 cells.
To determine whether the changes of AMPK and DMT1
observed in UOK262 cells were driven by loss of FH, we
compared the levels of these proteins in UOK262 and
UOK262-WT cells. Expression of wild-type FH in UOK262 cells
increased the levels of DMT1 and AMPKa (Figure 5C), suggest-
ing that the observed decreases in AMPKa and DMT1 levels
were attributable to the loss of functional FH in UOK262 cells.
Furthermore, activation of AMPK in UOK262 cells by glucose
limitation was accompanied by an increase in DMT1 levels
(Figure 5D), and increased iron uptake through DMT1 likely
accounted for the reduced activation of IRPs in UOK262 cells
grown in low glucose (Figures 2F and 5D).
Weaskedwhether reducedAMPK levels could lead to a reduc-
tion of DMT1 levels and thereby activate IRPs in UOK262 cells by
evaluating the response of non-HLRCC cells to treatment with
either the AMPK activator, metformin, or the AMPK inhibitor,CanAraA. Treatment of 786-0WT cells (Figure 5E) and UOK117C4
cells (data not shown) with metformin increased ACC-p and
DMT1 levels and decreased IRP activities, whereas treatment
with AraA concomitantly reduced AMPKa-p levels and DMT1
expression (Figure 5F). In addition, AMPKa-deficient MEFs
exhibited lower levels of DMT1 and increased levels of IRP2
compared with wild-type MEFs, further suggesting that AMPK
levels regulate IRP activities through changes in DMT1 expres-
sion (Figure 5G).
Recently, induction of p53 was shown to decrease IRP activ-
ities (Zhang et al., 2008), but the mechanism was unknown.
We observed that UOK262 cells had very low p53 levels (Fig-
ure 5H), consistent with our observation that AMPK is low in
UOK262 cells and reports that AMPK stabilizes p53 through
phosphorylation (Imamura et al., 2001; Jones et al., 2005). To
assess the role of p53 in IRP activation, we showed that induc-
tion of p53 increased DMT1 levels in p53ind cells (Figure 5I),
whereas control cells transfected with an empty vector exhibited
no change in DMT1 levels (data not shown). Conversely, siRNA-
mediated silencing of p53 in HEK293 cells decreased DMT1
levels (Figure 5J). These results suggested that AMPKmay regu-
late DMT1 expression in part through its effect on p53 levels.
FH-Deficient UOK268 Cells also Displayed Reduced
Levels of AMPK, p53, and DMT1, and Stabilization
of IRP2
To further confirm the significance of FH-AMPK-DMT1-IRP
pathway in HLRCC tumors, we examined UOK268 cells. Similar
to UOK262 cells, UOK268 cells displayed reduced levels of
AMPKa-p, ACC-p, AMPKa, AMPKb1, and p53 (Figure 6A–C).
We observed that DMT1 levels were low and IRP2 levels werecer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inc. 319
Figure 4. Reduced AMPK levels resulted in activation of anabolic factors ACC and S6, and activation of IRPs in UOK262 and control cells
(A) Levels of AMPKa-p (T172) in healthy kidney tissue and in renal tumors from three patients with HLRCC-associated kidney cancer were assessed by
immunohistochemistry (blue-black). Nuclei were stained with Methyl green. Scale bar represents 30 mm.
(B) Immunoblots of AMPKa-p (T172), ACC-p (S79) (upper panel) and AMPKa, AMPKb, Akt-p (S473) (lower panel) in UOK262 compared with non-HLRCC cells
(HK2, HEK293, and 786-0WT).
(C) Levels ofAMPKa1 andAMPKb1 transcripts (+/SD) in 786-0WT, UOK117C4, HEK293, and UOK262 cells were assessed by qRT-PCR. Data were normalized
with actin transcript levels and presented as fold-differences compared with those of UOK262 cells.
(D) GC/MS analysis of the AMP:ATP ratio in UOK262 cells and control HK-2 cells.
(E) Immunoblots of S6-p (an mTOR downstream effector) in cells that were serum-starved (0.5% serum) for 2 days and then stimulated with 20% serum for
30 min.
(F) Immunoblots of AMPKa-p, ACC-p, and IRP activities in 786-0WT cells that were cultured with or without AraA for 48 hr or 72h.
(G) Immunoblots of AMPKa-p, ACC-p, and IRP activities in 786-0WT cells that were cultured with or without metformin (Metf) for 72 hr.
(H) IRP activities in 786-0WT cells treated with the AMPK activator AICAR for 72 hr.
(I) Immunoblots of IRP2 in AMPKa-deficient MEFs compared with wild-type MEFs.
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results from a second HLRCC cell line confirmed that remodeling
of the AMPK pathway and intracellular iron homeostasis is
reproducible in FH-deficient RCC cell lines.
Key Elements of the Metabolic Profile of FH-Deficient
Cells can Be Recapitulated by Chemical Inhibition
of the TCA Cycle
Next, we asked whether inhibition of other TCA cycle enzymes
induced changes in AMPK, DMT1, and IRPs similar to those
observed in FH-deficient cells. Treatment with 2-thenoyltrifluor-
oacetone (TTFA), which inhibits SDH at the SDHD subunit (Sun
et al., 2005), resulted in increased IRP activities (Figure 7A) and
increased IRP2 and TfR1 protein levels (Figure 7B) in three
different non-HLRCC cell lines. As shown in Figure 2F, IRP acti-
vation in UOK262 cells was glucose-dependent. Similarly,
increasing glucose concentrations increased the TTFA-depen-
dent activation of IRPs (Figure 7C and D), whereas lowering
glucose concentrations abolished the effect of TTFA on IRP320 Cancer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inactivities (Figure 7C). Thus, inhibition of SDH activity by TTFA
recapitulated the IRP activation observed in FH-deficient cells.
Previous studies have shown that mitochondrial inhibitors can
have biphasic effects on AMPKa phosphorylation (Figure S4A).
Similarly, we observed that TCA cycle inhibition of non-HLRCC
cells with TTFA initially resulted in a rapid decrease in ATP levels
(Figure 7E) and a corresponding transient increase in AMPKa-p
(0.25h) (Figure 7F), followed by a partial recovery of ATP levels
(probably as a result of increased aerobic glycolysis) (Figure 7E)
and a decrease in AMPKa–p and AMPKa protein levels at later
time-points (Figure 7F). At the 48-h time point, there were overall
decreases in AMPKa and AMPKa-p levels, with corresponding
decrease in ACC-p and p53 levels, and increase in S6-p levels
(Figure 7G). More importantly, the long-term TTFA-mediated
decrease in AMPK levels correlated with diminished DMT1 levels
and increased IRP activities in both HEK293 and UOK117C4
cells (Figure 7H). In addition to TTFA, treatment with inhibitors
to other SDH subunits (3-NPA) and aconitase (MnCl2) also
led to reduced AMPKa-p levels and DMT1 expression, andc.
Figure 5. Reduced AMPK levels in UOK262 cells diminished the expression of the iron transporter DMT1, resulting in activation of IRPs
(A) Immunoblots of DMT1 (glycolysated forms at 70-100kDa) in UOK262 cells compared with HEK293 and 786-0WT cells.
(B) Immunoblots of DMT1 in HEK293, UOK117C4, and UOK262 cells that were treated with iron chelator Dfo for 16 hr.
(C) Comparison of AMPKa and DMT1 levels in HEK293, 786-0WT, UOK262, and UOK262-WT cells.
(D) Immunoblots of AMPKa-p and DMT1, and IRP activities in UOK262 cells cultured in different concentrations of glucose for 48 hr.
(E) Immunoblots of ACC-p and DMT1, and IRP activities in 786-0WT cells treated with metformin (72 hr), Dfo (16 hr), and/or FAC (16 hr).
(F) Immunoblots of AMPKa-p and DMT1, and IRP activities in 786-0WT cells treated with AraA for 48 hr.
(G) Immunoblots of AMPKa, DMT1 (unglycolysated form at 55 kDa) and IRP2 in AMPKa-deficient MEFs compared with wild-type MEFs.
(H) Immunoblots of p53 in UOK262 cells compared with HEK293 and 786-0WT cells.
(I) Effect of increased expression of p53 (induced by doxycycline treatment of p53ind cells) on DMT1 protein levels.
(J) Effect of siRNA-mediated silencing of p53 on the levels of DMT1 in HEK293 cells.
See also Figure S3.
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of the TCA cycle can cause non-cancer cells to remodel their
metabolism to include decreased AMPK and DMT1 levels
and activation of IRPs, similar to FH-deficient UOK262 and
UOK268 cells.
Silencing of HIF-1a and Activation of AMPK Reduced
the Tumorigenic Potential of UOK262 Cells
Previous studies have shown that elevation of HIF-2a is essential
for tumor growth of Von Hippel-Lindau (VHL)-deficient cells in
xenograft mouse models (Kondo et al., 2002; Maranchie et al.,
2002). Therefore, we compared HIFa levels in UOK262 cells (a
papillary type 2 RCC) with 786-0 cells (a VHL-deficient clear
cell RCC) (Figure 8A). In contrast to UOK262 cells, 786-0 cells
exhibited very low levels of HIF-1a and high levels of HIF-2a.
Compared with 786-0 cells, UOK262 cells also exhibited
decreased AMPKa-p, AMPKb1, and DMT1 levels, and increased
IRP2 levels. These distinctions between VHL-deficient and
FH-deficient cells suggest that disease-specific therapies could
be developed. Specifically, we observed that siRNA-mediated
silencing of HIF-1a (Figure 8B) or activation of AMPK using
metformin and AICAR (Figure 8C) markedly inhibited invasion
activities of UOK262 cells, suggesting that modulation of HIF-Can1a and AMPK signaling may offer opportunities for targeted
therapeutic approaches to the treatment of patients with
HLRCC-associated kidney cancer.
DISCUSSION
Fumarate hydratase-deficient kidney cancer, a clear example of
the Warburg effect in cancer, is an unusually aggressive form of
type 2 papillary kidney cancer that metastasizes when the
primary tumors are as small as 1 cm, and is nearly uniformly fatal
once it has spread beyond the kidney. Here, we showed that
HLRCC tumors and two different FH-deficient RCC cell lines
depended on glycolysis and had low AMPK levels. In addition
to promoting fatty acid and protein biosynthetic pathways
(through the activation of ACC and S6), low AMPK levels re-
duced the expression of DMT1 and activated IRP1 and IRP2
(Figure 8D). Our studies demonstrated that p53 enhances
expression of DMT1 (Figure 5I), and the AMPK-dependent
reduction of p53 would thus be expected to cause cytosolic
iron deficiency, activation of IRPs, and translational repression
of the iron-storage protein ferritin. Previous studies have shown
that synthesis of ferritin is decreased in cells that are stimulated
by several oncogenes (Tsuji et al., 1995; Wu et al., 1999). Ourcer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inc. 321
Figure 6. A second glycolytic HLRCC cancer cell line, UOK268, ex-
hibited decreased levels of AMPK, DMT1 and p53
(A) Immunoblots of AMPKa-p, ACC-p (an AMPK effector), DMT1, and IRP2 in
UOK268 compared with HEK293 and 786-0WT cells.
(B) Immunoblots of AMPKa, AMPKb, and DMT1 levels in UOK268 cells
compared with HEK293, 786-0WT, and UOK262 cells.
(C) Immunoblots of p53 in UOK268 compared with HEK293, 786-0WT, and
UOK262 cells.
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increased expression of DMT1 (Figure 5I), providing one mech-
anism for the previously reported p53-dependent decrease in
IRP activities and increase in ferritin levels (Zhang et al., 2008).
In respiring cells, DMT1 expression is important for the uptake
of iron for the biosynthesis of heme and Fe-S cluster cofactors
in the mitochondrial respiratory complexes. The AMPK-depen-
dent decrease of DMT1 levels may represent an integral part
of the metabolic shift to glycolysis, because less iron may
be needed to support energy metabolism in glycolytic cells
compared with respiring cells. In addition, when cells are
required to produce energy from glycolysis, low iron levels
may consolidate the shift to glycolysis by stabilizing HIF-1a or
other participants in the remodeled metabolism of FH-deficient
cells.
Previous studies have shown that elevation of HIFa levels in
FH-deficient cells resulted from fumarate accumulation, which
inhibits the PHDs thatmark HIFa proteins for degradation (Isaacs
et al., 2005; Pollard et al., 2005). However, many other factors
may also contribute to FH-associated neoplasias. We suggest
that HIF1a is increased in HLRCC in part because cytosolic
iron deficiency also inhibits PHD activities and contributes to
the stabilization of HIF-1a proteins. Furthermore, because the
HIF-2a transcript contains an IRE in its 50UTR (Sanchez et al.,
2007), whereas the HIF-1a transcript does not, activation of
IRPs would be expected to selectively repress HIF-2a transla-
tion. We suggest that IRP activation explains why HIF-1a levels
were markedly elevated, whereas HIF-2a protein levels were
very low in UOK262 and UOK268 cells (Figure 3B and 3C),
even though HIF-2a transcript levels in UOK262 cells were
comparable with control cells (Figure 3E).322 Cancer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier InThe differential expression levels of HIFa proteins in 786-0 and
UOK262 cells (Figure 8A) have important implications for the
development of targeted therapeutic treatment of VHL-deficient
and FH-deficient RCC. Although HIF-1a has been shown to
promote tumorigenesis in colon and pancreatic cancer cells
(Chen et al., 2003; Dang et al., 2006), studies in RCC have shown
that activation of HIF-2a, and not HIF-1a, is necessary for the
tumorigenesis of VHL-deficient RCC (Kondo et al., 2002; Maran-
chie et al., 2002). HIF-1a and HIF-2a have both overlapping as
well as distinct targets (Gordan andSimon, 2007; Kaelin andRat-
cliffe, 2008; Raval et al., 2005), and HIF-1a is uniquely involved in
activating genes associated with glycolysis (Gordan and Simon,
2007; Haase, 2010). In this study, we showed that silencing of
HIF-1a inhibited the invasion activities of UOK262 cells (Fig-
ure 8B), further suggesting that elevation of HIF-1a is critical for
engineering the switch to glycolytic metabolism in UOK262 cells.
Notably, the coordination that we observed here between
glucose and iron metabolisms in FH-deficient RCC has an
evolutionary precedent in the metabolism of Saccharomyces
cerevisiae. When grown in glucose-rich medium, S. cerevisiae
uses fermentation (a microbial equivalent of glycolysis) as its
main metabolic pathway, and repression of the yeast AMPK
homolog, SNF1, represses expression of iron uptake genes
(Haurie et al., 2003). As glucose concentrations decrease, acti-
vation of SNF1 induces expression of iron uptake genes and
facilitates the shift to oxidative metabolism. Conversely, iron
deficiency in S. cerevisiae results in phosphorylation of SNF1,
which increases glucose uptake and glycolysis, allowing the
cells to switch from respiratory to fermentative metabolism
(Puig et al., 2008). Our results suggest that the high glycolytic
flux in UOK262 cells reduces AMPK and DMT1 expression
levels, whereas glucose depletion diminished glycolysis and
increased AMPK signaling and DMT1 expression (Figure 5D).
These studies suggest that AMPK/SNF1 signaling provides an
evolutionarily conserved linkage between intermediary metabo-
lism and intracellular iron homeostasis. Interestingly, although
the activities of several Fe-dependent enzymes, including respi-
ratory complex I and cytosolic aconitase, were low in UOK262
cells (Figure 1D and 2C), mitochondrial aconitase activities
were not diminished in UOK262 cells (Figure 2C), suggesting
that these cells can preferentially direct iron to specific proteins
or pathways.
Although previous studies on AMPK signaling have largely
focused on the increase in AMPKa phosphorylation and its role
in increasing catabolism during the acute response to metabolic
stress (Hardie, 2007), fewer studies have characterized the
potential importance of low AMPK activity in promoting activities
of anabolic pathways in tumorigenesis (Jones and Thompson,
2009; Luo et al., 2005; Shaw, 2006). Here, we not only showed
that levels of AMPKa-p were diminished in FH-deficient cells,
but we also found that AMPK signaling was also regulated at
the transcript and/or protein levels (Figure 4B and 4C). This
metabolic remodeling was not unique to FH-deficient cells,
because chemical inhibition of SDH in non-cancer cells also
resulted in reduced levels of AMPK, p53, ACC-p, and DMT1,
and increased levels of S6-p (Figure 7). Time-course studies indi-
cated that, upon chemical inhibition of SDH, changes of AMPK
activities inversely correlated with changes in intracellular ATP
levels: ATP levels decreased initially upon SDH inhibition, andc.
Figure 7. Chemical inhibition of SDH in non-HLRCC cells can induce metabolic changes similar to those observed in FH-deficient UOK262
cells
(A) IRP activities were assessed in 786-0WT, UOK117C4, and HEK293 cells that were treated with TTFA, an inhibitor of SDH, for 48 hr.
(B) Immunoblots of IRP2 and TfR1 in 786-0WT cells treated with TTFA.
(C) IRP activities in 786-0WT cells treated with TTFA at different glucose concentrations.
(D) Immunoblots of IRP2 and TfR1 in 786-0WT cells treated with TTFA at different glucose concentrations.
(E) Time-dependent effect of 1 mM TTFA treatment on ATP levels (+/ SD) in HEK293 cells.
(F) Time-dependent effect of 1 mM TTFA treatment on the levels of AMPKa and AMPKa-p in HEK293 and 786-0WT cells as assessed by immunoblot analysis.
(G) Effect of TTFA treatment for 48 hr on the levels of AMPKa-p, AMPKa, AMPKb, ACC-p, p53, and S6-p in HEK293 cells.
(H) Effect of TTFA treatment of HEK293 and UOK117C4 cells for 48 hr on the levels of AMPKa-p, ACC-p, DMT1, and IRP activities.
See also Figure S4.
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whereas after an initial rapid increase, AMPKa-p levels dropped
below the levels of untreated cells (Figure 7F). After a 48-hr treat-
ment with TTFA, there was also a marked decrease in AMPKa
protein levels (Figure 7G), which further ensured that levels of
AMPKa-p decreased regardless of the AMP:ATP ratio. These
results are similar to the decreased levels of AMPKa-p, AMPKa,
and AMPKb1 proteins and transcripts that were observed in
FH-deficient cells (Figures 4B and 4C), and they show that the
obligate shift to glycolysis in FH-deficient cells produces associ-
ated changes in AMPK activity that enhance anabolic reactions.
The high glycolytic rate, together with the decrease of AMPK
signaling, can provide several potential growth advantages to
FH-deficient RCC. Although the yield of ATP per glucose mole-
cule is higher in OXPHOS than in glycolysis, aerobic glycolysis
can provide sufficient energy for cell proliferation provided the
glycolytic flux is high enough (DeBerardinis et al., 2008). Aerobic
glycolysis can also confer growth advantages by diverting some
of the glucose into pathways that generate NADPH, acetyl-CoA,
and ribose for fatty acid, protein, and nucleotide synthesis
(Vander Heiden et al., 2009). Reduced AMPK activities wouldCanpromote the efficient use of the NADPH, acetyl-CoA, and ribose
generated by aerobic glycolysis by activating anabolic factors
involved in protein and fatty acid synthesis (Hardie, 2007).
Many cancers are characterized by upregulation of anabolic
factors such as ACC, FAS, and mTOR, all of which are inhibited
by AMPK activation (Jones and Thompson, 2009; Luo et al.,
2005; Shaw, 2006). Notably, reduced AMPK phosphorylation
was recently reported in breast cancer specimens (Hadad
et al., 2009). Alterations in the LKB1/AMPK/TSC/mTOR pathway
are associated with a wide variety of cancers and hamartomas,
including Peutz-Jeghers syndrome and tuberous sclerosis
complex (Inoki and Guan, 2009; Jones and Thompson, 2009;
Shaw, 2006). The tumor suppressor, p53, is a downstream
effector of AMPK, and p53 mutations are found in 50% of all
human cancers (Vousden and Ryan, 2009). Here, we established
that diminished p53 levels result from AMPK-dependent meta-
bolic remodeling, adding to the potential mechanisms that
impair p53 function in tumorigenesis. Thus, the marked increase
in glycolysis and reduced AMPK levels in FH-deficient cancer
cells together may promote anabolic metabolism (through the
activation of ACC and S6) and repress senescence andcer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inc. 323
Figure 8. Silencing ofHIF-1a and activationof AMPK reduced the invasive potential of the FH-deficientUOK262cells, which have a distinctive
metabolic profile
(A) Immunoblots of HIF-1a, HIF-2a, AMPKa-p, AMPKb, DMT1, IRP2 in UOK262 compared with 786-0 cells.
(B) Effect of siRNA-mediated silencing of HIF-1a on the invasion activities of UOK262 cells measured using the RT-CIM cell invasion monitoring system.
(C) Effect of treatment with the AMPK activators metformin and AICAR on the invasion activities of UOK262 cells.
(D) A working model for FH-deficient cells, in which impairment of the TCA cycle imposes a need to shift energy production from respiration to glycolysis, and
induces an AMPK-dependent decrease in p53 and activation of anabolic factors ACC and S6. Reduced AMPK levels decrease expression of the DMT1 iron
transporter, resulting in reduced iron uptake and activation of IRPs. While reduced cytosolic iron levels and fumarate accumulation are expected to inhibit PHDs
and stabilize both HIF-1a and HIF-2a proteins, activation of IRPs would selectively repress HIF-2a translation and attenuate the potential increase in HIF-2a
proteins. The increased expression of HIF-1a and glycolytic shift, coupled to decreases of AMPK and p53 levels, and increased activity of anabolic pathways
(shown in orange) may all confer growth/survival advantages to FH-deficient RCC.
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Altered Glucose and Iron Metabolisms in FH/ RCCapoptosis (as a result of the decrease of p53 levels) (Vousden
and Ryan, 2009) in a manner conducive to cancer cell prolifera-
tion (Figure 8D).
Our demonstration that metformin and AICAR reduced the
invasion activities of UOK262 cells (Figure 8C) is consistent
with previous studies that showed that metformin and AICAR
inhibited the proliferation of various cancer cell lines (Buzzai
et al., 2007; Hirsch et al., 2009; Xiang et al., 2004), and that
diabetics treated with metformin exhibited decreases in cancer
incidence (Evans et al., 2005). Metformin can inhibit tumorigen-
esis by activating AMPK, and thereby inhibiting anabolic path-
ways (Shaw, 2006) and inducing apoptosis (Buzzai et al., 2007).
However, our findings also suggest another potential mechanism
for the anti-cancer effect of metformin: induction of DMT1324 Cancer Cell 20, 315–327, September 13, 2011 ª2011 Elsevier Inexpression (Figure 5E) may increase iron uptake, which may
reduce HIF-1a levels and associated glycolysis, while promoting
oxidative damage to DNA, proteins, and lipids in cancer cells.
Interest in theWarburg effect (Vander Heiden et al., 2009;War-
burg, 1956) has been rekindled by the mounting appreciation for
the growth advantages that glycolysis can confer to tumor cells
(Shaw, 2006; Vander Heiden et al., 2009; Warburg, 1956). In
neoplasia, oncogenic pathwaysmay function to drive cell-auton-
omous nutrient uptake and anabolic metabolism via aerobic
glycolysis (Vander Heiden et al., 2009). We propose that the
AMPK-dependent decrease in iron uptake in FH-deficient cells
reflects a reversion to an evolutionarily conserved pathway that
coordinates glucose and iron metabolisms. Our results suggest
that a fundamental feature of HLRCC carcinogenesis involvesc.
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Altered Glucose and Iron Metabolisms in FH/ RCCreduced AMPK activities, which mediate a global remodeling of
anabolic processes and ironmetabolism to enhance cell prolifer-
ation and survival. The metabolic shift to aerobic glycolysis
described in this aggressive form of cancer could provide insight
into the most fundamental aspects of tumorigenesis and provide
opportunities for the development of improved diagnostics and
therapeutics in tumors characterized by aerobic glycolysis and
impaired oxidative phosphorylation.
EXPERIMENTAL PROCEDURES
Cell Cultures and Animal Studies
Kidney cell lines used in this study are summarized in Table S1. p53ind
and control p53- cell lines were generous gifts from the Torti lab (Wake Forest
University). AMPK+/+ andAMPK/MEFswere generous gifts fromDrBenoit
Viollet (Universite´ Paris Descartes, CNRS). All cells were cultivated in DMEM
containing 25 mM D-glucose, 1 mM pyruvate, 10% fetal bovine serum, and
2 mM L-glutamine. Embryonic fibroblasts of 13-day-old embryos were iso-
lated from wild-type and IRP1/ mice as previously described (LaVaute
et al., 2001). For xenograft studies, UOK 262 or UK262-WT cells (5 3 106)
were injected subcutaneously into 10 athymic nude mice and tumor growth
was followed by measurements of tumor volume over time. All protocols
were approved by the NICHD Animal Care and Use Committee and met NIH
guidelines for the humane care of animals.
Immunoblots
Immunoblots were performed on 1% Triton lysate, whole-cell lysates (RIPA
buffer or 4% SDS in PBS) or nuclear extracts. Equal loading was assessed
by Ponceau Red staining and immunoblot with anti-tubulin or anti-CREB anti-
bodies. Antibodies are described in supplementary information.
IRP Activity Assays
Assay samples containing 25 mM Tris-HCl (pH7.5), 40mM KCl. 5% glycerol,
0.1U/uL SuperRNAsine (Ambion, Austin, TX), 0.3 uL/uL yeast tRNA, 2.5 mM
DTT and 10 nM P32-labeled IRE of human ferritin H chain and 10 ug protein
were loaded onto a 8% acrylamide/TBE gel and run at 200 V for 5 hr at
room temperature. Equal loading was assessed by immunoblot with IRPs
and anti-tubulin antibodies.
Measurements of Metabolic Status
Cells were cultured in custom XF96 microplates (Seahorse Bioscience, Chic-
opee, MA). Respiration and glycolysis cause rapid changes to the concentra-
tions of dissolved oxygen and free protons in the medium above a monolayer
of cells, which are measured by solid-state sensor probes in the XF96
Analyzer. Glucose (25 mM) was injected at the indicated time-points into
each well after baseline rate measurement. Analysis of TCA cycle intermedi-
ates, ATP and AMP, were performed using GC/MS analyses of 6 samples
by Metabolon, Inc. (Durham, NC).
Invasion Assays
RT-CIM cell invasion and migration monitoring system (ACEA Biosciences,
San Diego, CA) was used to measure invasion of UOK262 cells transfected
by electroporation (AMAXA) with 10 uM of HIF-1a siRNA or mock RNA, or
UOK262 cells treated with 2 mM metformin or 1 mM AICAR. One-day post-
transfection, cells were serum-starved overnight before being plated in the
upper chambers, whereas the lower chambers contained media with 10%
serum. Impedance signals from invasive cells passing through the membrane
between the chambers were recorded in real-time to provide quantitative
information about the number of migrating cells.
Human Materials
All human subjects work was approved by NCI Institutional Review Board
Committee. Renal tumors from patients affected with HLRCC were removed
surgically at the NIH. Informed consent was obtained from all subjects.
Patients were evaluated on approved NCI-IRB protocols 97-C-0147 and/or
03-C-0066.CanData Analysis
All data are representative of three or more independent experiments. Statis-
tical analyses were performed by Student’s t test for paired samples.
Additional information on experimental procedures is described in the
on-line supplemental information.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.ccr.2011.07.018.
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